Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis

 Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis

Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis

Shots:

  • The US FDA has accepted to review a BLA for tanezumab (2.5 mg, SC), being evaluated for patients with chronic pain due to mod. to sev. OA with inadequate pain relief with other analgesics
  • The regulatory submission is based on data from 39 P-I-III clinical studies assessing tanezumab in 18,000 patients, including three P-III studies evaluating tanezumab (SC) in patients with mod. to sev. OA
  • Tanezumab is an investigational mAb targeting & inhibiting NGF with its anticipated PDUFA date in Dec’2020. In 2013, Pfizer & Eli Lilly collaborated to develop and commercialize tanezumab as non-opioid pain medication addressing the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: Eli Lilly  | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post